Arrowgrass Capital Partners (US)’s AbbVie ABBV Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-178,500	Closed	-$17.3M	–	135
2017 Q4	$17.3M	Buy	178,500 +176,715	+9,900%	+$16.7M	0.17%	150
2017 Q3	$15.9M	Hold	1,785	–	–	0.12%	212
2017 Q2	$12.9M	Sell	1,785 -376	-17%	-$25.3K	0.1%	259
2017 Q1	$14.1M	Buy	2,161 +416	+24%	+$26.2K	0.14%	196
2016 Q4	$10.9M	Buy	1,745 +1,092	+167%	+$66.7K	0.12%	169
2016 Q3	$4.12M	Hold	653	–	–	0.06%	234
2016 Q2	$4.04M	Sell	653 -6,991	-91%	-$426K	0.04%	212
2016 Q1	$43.7M	Buy	7,644 +6,090	+392%	+$339K	0.52%	33
2015 Q4	$9.21M	Sell	1,554 -858	-36%	-$49.4K	0.11%	113
2015 Q3	$13.1M	Buy	2,412 +418	+21%	+$27.2K	0.25%	74
2015 Q2	$13.4M	Sell	1,994 -6,206	-76%	-$405K	0.2%	102
2015 Q1	$48M	Buy	+8,200	New	+$495K	0.74%	21

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s ABBV Position: Q4 2019 in Review

Arrowgrass Capital Partners (US) reduced its AbbVie (ABBV) stake by 57% in Q4 2019, selling an estimated $7.31M and leaving 65,970 shares worth $5.84M. The position accounts for 1.54% of the portfolio, ranked #24.

Arrowgrass Capital Partners (US) first reported a position in ABBV in Q1 2015 and has held it in 14 quarters since. The position peaked at $11.7M in Q3 2019. 2,244 funds tracked by Wall St. Rank hold ABBV as of Q4 2019.

Arrowgrass Capital Partners (US) held 65,970 shares of AbbVie worth $5.84M as of Q4 2019.
Arrowgrass Capital Partners (US) sold 88,100 AbbVie shares in Q4 2019, an estimated $7.31M.
AbbVie made up 1.54% of Arrowgrass Capital Partners (US)'s portfolio in Q4 2019, its #24 holding.
Arrowgrass Capital Partners (US) first reported a position in AbbVie in Q1 2015 and has held it in 14 quarters since.
Arrowgrass Capital Partners (US)'s AbbVie position peaked at $11.7M in Q3 2019.
2,244 funds tracked by Wall St. Rank held AbbVie as of Q4 2019.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q4 2019, filed 14 Feb 2020.